

# Xiaotong Zhang

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1886826/xiaotong-zhang-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48 papers	279 citations	9 h-index	14 g-index
54 ext. papers	414 ext. citations	3.3 avg, IF	3.65 L-index

#	Paper	IF	Citations
48	Second primary tumor after immune checkpoint inhibitor therapy: A case report.. <i>Thoracic Cancer</i> , <b>2022</b> ,	3.2	2
47	Predictive Value of Echocardiographic Strain for Myocardial Fibrosis and Adverse Outcomes in Autoimmune Diseases.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9, 836942	5.4	0
46	Response to letter to the editor by Zhang et al.. <i>European Journal of Neurology</i> , <b>2022</b> ,	6	
45	Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis.. <i>Thoracic Cancer</i> , <b>2022</b> ,	3.2	1
44	Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.. <i>Journal of Neurology</i> , <b>2022</b> , 1	5.5	0
43	Myocarditis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e14579-e14579	2.2	
42	Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. <i>Cancer Medicine</i> , <b>2021</b> , 10, 188-198	4.8	6
41	Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 357-363	3.2	5
40	Blood eosinophil count-guided corticosteroid therapy and as a prognostic biomarker of exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>Therapeutic Advances in Chronic Disease</i> , <b>2021</b> , 12, 20406223211028768	4.9	6
39	Correlation between total homocysteine and cerebral small vessel disease: A Mendelian randomization study. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 1931-1938	6	13
38	High Level of Uromodulin Increases the Risk of Hypertension: A Mendelian Randomization Study. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 736001	5.4	1
37	Effects of laser debonding treatment on the optical and mechanical properties of all-ceramic restorations. <i>Lasers in Medical Science</i> , <b>2021</b> , 36, 1497-1504	3.1	1
36	Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period.. <i>Thoracic Cancer</i> , <b>2021</b> ,	3.2	1
35	A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920965849	5.4	2
34	Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1869-1875	3.2	1
33	Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non-small-cell lung cancer and ERBB2 mutation. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2051-2055	3.2	7
32	Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2339-2342	3.2	2

31	Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1216-1223	3.2	4
30	Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy. <i>European Journal of Cancer</i> , <b>2020</b> , 128, 57-59	7.5	5
29	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2406-2430	3.2	14
28	Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 594-602	3.2	9
27	Histologic transformation of lung cancer during pembrolizumab therapy: A case report. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 793-796	3.2	4
26	Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1746-1751	3.2	6
25	Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1647-1654	3.2	9
24	Opportunistic bowel infection after corticosteroid dosage tapering in a stage IV lung cancer patient with tislelizumab-related colitis. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1699-1702	3.2	2
23	Prediction of OCT images of short-term response to anti-VEGF treatment for neovascular age-related macular degeneration using generative adversarial network. <i>British Journal of Ophthalmology</i> , <b>2020</b> , 104, 1735-1740	5.5	10
22	Non-motor Symptoms in Chinese Patients With Isolated Generalized Dystonia: A Case-Control Study. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 209	4.1	3
21	Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1621-1632	3.2	18
20	Influenza in hospitalized cancer patients: A propensity score matching analysis.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 170-170	2.2	
19	Lacune and Large Perivascular Space: Two Kinds of Cavities Are of Different Risk Factors and Stroke Risk. <i>Cerebrovascular Diseases</i> , <b>2020</b> , 49, 522-530	3.2	3
18	NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 5975-5985	3.6	3
17	Influenza in hospitalised patients with malignancy: a propensity score matching analysis. <i>ESMO Open</i> , <b>2020</b> , 5, e000968	6	0
16	A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test. <i>Tumor Biology</i> , <b>2020</b> , 42, 1010428320958603	2.9	2
15	Opportunistic infections complicating immunotherapy for non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1689-1694	3.2	4
14	Association between lipoprotein(a) concentration and the risk of stroke in the Chinese Han population: a retrospective case-control study. <i>Annals of Translational Medicine</i> , <b>2020</b> , 8, 212	3.2	6

13	Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 551-556	3.2	25
12	A validated ultra-HPLC-MS/MS method for determination of honokiol in human plasma and its application to a clinical pharmacokinetic study. <i>Bioanalysis</i> , <b>2019</b> , 11, 1085-1098	2.1	3
11	Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease. <i>OncoTargets and Therapy</i> , <b>2019</b> , 12, 5545-5549	4.4	3
10	Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. <i>Lung Cancer</i> , <b>2018</b> , 122, 1-6	5.9	13
9	Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1056-1061	3.2	5
8	Rebiopsy status among non-small cell lung cancer patients after Icotinib therapy in China.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e21146-e21146	2.2	
7	ERBB2 mutation profiling with next-generation sequencing (NGS) in solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e24264-e24264	2.2	
6	Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 7513-7519	4.4	4
5	Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. <i>Lung Cancer</i> , <b>2018</b> , 125, 142-149	5.9	16
4	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2018</b> , 122, 32-37	5.9	27
3	The ability of avitinib to penetrate the blood brain barrier and its control of intra-/extra- cranial disease in patients of non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e20613-e20613	2.2	5
2	Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China. <i>Clinica Chimica Acta</i> , <b>2015</b> , 438, 388-95	6.2	26
1	The role of epidermal growth factor receptor mutations (EGFRm) in NSCLC with leptomeningeal metastasis: A prospective observational study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e19070-e19070	2.2	